GlassScriptPhysician profile
Matthew James Mcgehee
NPI 1215058607
$4,371.58
in general payments reported to CMS, 2019-2025
14 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $27.18 · 2021: $32.63 · 2022: $2,934 · 2023: $438 · 2024: $306 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,771.69 | 2019-2025 | Proclaim, Eterna |
| Spr Therapeutics, INC | $239.59 | 2022-2025 | Sprint Pns System |
| Biogen, INC. | $63.42 | 2024-2025 | Vumerity, Tysabri |
| Abbvie INC. | $62.95 | 2024-2025 | |
| Acorda Therapeutics, INC | $37.70 | 2024 | Inbrija, Ampyra |
| Mdd US Operations, LLC | $28.91 | 2024 | Gocovri |
| Cycle Pharmaceuticals INC | $26.80 | 2025 | Bafiertam |
| Lundbeck LLC | $26.50 | 2024 | Vyepti |
| Ucb, INC. | $25.82 | 2024 | Rystiggo |
| Acadia Pharmaceuticals INC | $22.42 | 2024 | Nuplazid |
| Banner Life Sciences, LLC | $18.53 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $17.46 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.39 | 2025 | Ultomiris |
| Si-Bone, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcgehee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.